AG-01 Compound not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses. Phase 1B patients will be treated with AG-01 at the RP2D.”In the company’s words, NCT05627960 on ClinicalTrials.gov
- Tested for
- Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma
- Main trialPhase 1
- “This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal antibody expressed in a CHO production cell line. The antibody AG01 binds to human PGRN/GP88, expressed on cancer cells. This study will have a dose escalation portion (1A) to evaluate maximum tolerated dose (MTD) and/or maximum administered dose (MAD), the safety and tolerability of AG01treatment before the dose expansion portion (1B) of the study is initiated. The dose escalation portion of this study (1A) will also…”In the company’s words, NCT05627960 on ClinicalTrials.gov
Other drugs for Triple Negative Breast Cancer
- PembrolizumabMerck & Co. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Sacituzumab govitecanGilead (Kite) · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
- ESG401Qilu Pharmaceutical · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jun 2026 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026